Zimmer Partners’s Mersana Therapeutics MRSN Stock Holding History

Zimmer Partners’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-800	Closed	-$279K	–	87
2017 Q2	$279K	Buy	+800	New	+$277K	0.01%	85

Other funds holding MRSN

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Zimmer Partners's MRSN Position: Q3 2017 in Review

Zimmer Partners sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 800 shares — an estimated $279K sold.

Zimmer Partners first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $279K in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

Zimmer Partners reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
Zimmer Partners sold 800 Mersana Therapeutics shares in Q3 2017, an estimated $279K.
Zimmer Partners first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
Zimmer Partners's Mersana Therapeutics position peaked at $279K in Q2 2017.
42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Zimmer Partners's 13F filing for Q3 2017, filed 14 Nov 2017.